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                                 Case Report  
 
Classical morphea lesion  
USE OF EXCIMER LASER FOR MORPHEA 
Samah Hajjar, M.D. , Sarah  Beggs, B.S. , Alison Ehrlich, M.D. 
George Washington University, Medical Faculty Associates, Department of Dermatology 
• Morphea, also known as localized scleroderma (LS), is an 
idiopathic sclerotic inflammatory disorder that primarily affects the 
skin but has the potential to involve fascia, muscle and bones.  
 
• The disease manifests initially as erythematous lesions that 
eventually transition into hypo/hyperpigmented sclerotic plaques. 
 
• Unlike systemic sclerosis, LS spares the internal organs from 
fibrosis. However, extra-cutaneous morbidities are common with 
morphea and include myalgia, arthralgia, musculoskeletal 
limitations, neurological symptoms, and ocular complications.  
 
• There are three primary mechanisms involved in the development 
of LS: stimulation of T cell lymphocytes causing the release of pro-
inflammatory cytokines, dysregulation of connective tissue 
metabolism, and damage to the microvasculature. 
 
• With no cure for this disfiguring disease, therapeutic modalities 
including topical regiments, immunosuppressive agents, antimalarial 
medications, and phototherapy are used to manage the symptoms 
and progression. While many treatments options are available, they 
vary in efficacy. 
 
• Several studies have demonstrated the benefit of phototherapy for 
morphea confined to the cutaneous layer. Three central 
mechanisms seem to contribute to the effectiveness of 
phototherapy: breakage of DNA strands of T lymphocytes causing 
apoptosis, immunomodulation of the IL-6 collagen stimulating 
cytokine and IL-8 pro-inflammatory cytokine, and stimulus of 
fibroblasts to produce collagenase. Studies have demonstrated the 
308 nm wave length, used in the excimer laser, is the most efficient 
wavelength for inducing DNA breakage in lymphocytes. 
 
• We are reporting the use of excimer laser for active sclerotic 
morphea plaques. To our knowledge, this is the first description of 
excimer laser for the treatment of morphea. 
 
 
Morphea plaque of our patient  after 
16 treatments 
• We present a case of a 28-year-old woman with active sclerotic 
plaques distributed along her neck, left flank. She had previously 
failed therapy with topical steroids and methotrexate, and was started 
on hydroxychloroquine 400 mg daily and 
calcipotriene/betamethasone ointment 0.005% BID. Since she was 
still having active lesions, she was referred to our clinic for 
consultation regarding excimer laser therapy.  
 
 Method 
• 28 years old woman with active morphea lesions on her neck and left 
flank.  
• Patient had one treatment at 300 mJ and experienced increased 
erythema at left flank lesion for more than 24 hours. 
• She then had her dose decreased and held at 260 mJ. 
• We continued her current regiment of hydroxychloroquine 400 mg 
daily and calcipotriene/betamethasone ointment 0.005% twice a day. 
 Result  
• After two months (16 treatment sessions), she had no progression of 
her current lesions and peripheral erythema of these lesions resolved. 
Conclusion 
• In conclusion, we present excimer laser as an adjunct therapy 
option for morphea. Being a potentially disfiguring disease with a 
subset of patients failing multiple treatment regiments, we believe the 
308-nm excimer laser can provide another option. The successful 
management of our patient’s morphea using the 308-nm excimer 
laser in addition to conventional therapy demonstrates the potential 
benefit of excimer laser for morphea.  To our knowledge, this is the 
first description of excimer laser for the treatment of morphea. 
